$1.91
+0.00 (+0.00%)
Open$1.92
Previous Close$1.91
Day High$1.93
Day Low$1.89
52W High$12.25
52W Low$1.40
Volume—
Avg Volume655.4K
Market Cap128.00M
P/E Ratio—
EPS$-2.08
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+3,320.4% upside
Current
$1.91
$1.91
Target
$65.33
$65.33
$48.23
$65.33 avg
$96.03
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 102.93M | 108.44M | 88.87M |
| Net Income | -18,276,199 | -22,730,064 | -15,420,094 |
| Profit Margin | -17.8% | -21.0% | -17.4% |
| EBITDA | -27,166,221 | -28,388,210 | -21,820,067 |
| Free Cash Flow | -19,844,248 | -21,752,544 | -13,746,863 |
| Rev Growth | +6.4% | +6.6% | +8.6% |
| Debt/Equity | 0.41 | 0.31 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |